American Association for Cancer Research, Cancer Discovery, 11(3), p. 1220-1221, 2013
DOI: 10.1158/2159-8290.cd-13-0667
Full text: Download
Abstract Summary: Targeted therapeutic approaches have seen tremendous advances in the last decade, for good reason. Specifically intervening with a disease-causing gene can revert the deleterious phenotype while eliminating the toxicity often associated with broad-spectrum agents. Unfortunately, because these selective agents hit one target in a single location, acquired resistance is often high. An arguably better treatment approach includes coupling multiple targeted agents or using an agent that hits an individual target in several independent locations and/or alters multiple relevant targets in the disease-causing pathway(s), precisely the approach taken by Nishimura and colleagues in their recent report aimed at identifying a better treatment option for ovarian cancer. Cancer Discov; 3(11); 1220–1. ©2013 AACR. See related article by Nishimura et al., p. 1302